Skip to content
NewsBlazeIN – Lifestyle
Author:
NervGen Pharma Corp.
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
May 18, 2026
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
April 27, 2026
NervGen Pharma to Participate in the H.C. Wainwright “HCW@Home” Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
April 13, 2026
NervGen Pharma to Participate in the H.C. Wainwright “HCW@Home” Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
April 13, 2026
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
April 7, 2026
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
March 31, 2026
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
March 13, 2026